BD (NYSE: BDX) announced plans to eliminate 60 positions at its manufacturing facility based in Drogheda, Ireland.
A statement provided by a BD spokesperson confirmed a targeted reduction of 60 positions due to a combination of factors. These include the effects of the COVID-19 pandemic and the company’s spinoff of its diabetes business, Embecta.
The company announced the creation of 100 new jobs at the Drogheda facility, plus a €62 million investment there, in December 2021. This investment aimed to upgrade site equipment and expand production of its PosiFlush syringes.
BD plans for the reduction to take place over 15 months to right-size manufacturing operations with “today’s realities.”
